-
U.S. crude oil production plunges nearly 40% on record, severe cold freezes oil well operations
Time of Update: 2021-11-21
According to government data, before the onset of the cold wave, the United States produced approximately 11 million barrels of oil per day .
The largest oil field in the United States, the Permian Basin, was the most severely affected area, with production reduced by 65% to 80% from normal levels .
-
Chinese scholars propose innovative treatment plans for Chinese liver cancer patients
Time of Update: 2021-11-01
In recent years, Chinese scholars have proposed hepatic arterial infusion chemotherapy (FOLFOX-HAIC) with fluorouracil, leucovorin and oxaliplatin regimens for the treatment of large liver cancer .
In 2017, Shi Ming’s team initially revealed the safety and effectiveness of FOLFOX-HAIC in the treatment of large liver cancer in a phase II study .
-
A new method for detecting autoimmune diseases by ferritin multimeric antigen-antibody
Time of Update: 2021-08-10
In order to improve the diagnosis efficiency of autoimmune diseases, the team of Academician Yan Xiyun of the Institute of Biophysics of the Chinese Academy of Sciences and the team of Professor Li Zhanguo from Peking University People’s Hospital have developed a multimeric antigen based on ferritin display and multimeric secondary antibody detection using pSS as a research model.
-
Moutai 1.9 billion hospitals
Time of Update: 2021-07-10
According to media reports, Moutai, which has a market value of 2 trillion yuan, is about to open a hospital for the establishment of schools and airports .
Moutai Hospital, which is about to operate in June, will start recruiting in the near future .
-
Horde Biosciences completes A++ round of financing, Yuansheng Venture Capital leads the investment
Time of Update: 2021-06-12
Recently, a cutting-edge company dedicated to advancing disease treatment through human induced pluripotent stem cell technology-Hodder Biosciences announced that it has completed nearly 100 million yuan in A++ round of financing, led by Yuansheng Venture Capital, and original shareholders Longmen Capital and Huacheng Venture Capital Follow the vote.
-
New Sharp | Technolab completes 450 million yuan A round of financing, Hillhouse Ventures leads the investment
Time of Update: 2021-05-09
Zheng Weihong, co-founder and CEO of Techno Microlab, said: “In this joint investment, Hillhouse Ventures is highly recognized by the leading investment institutions; Kangzhe Pharmaceutical’s representative product pipeline meets the market demand for accurate judgment; Ming Bio represents the world's leading level in the field of biopharmaceutical technology.
-
2021 AACR | Repetinib China Data Appears on the World's Top Cancer Research Arena
Time of Update: 2021-05-09
This study was led by the team of Professor Lin Shen from Peking University Cancer Hospital, and explored the pharmacokinetic (PK) characteristics of repetinib and its active metabolites in patients with gastrointestinal stromal tumor (GIST) in China.
-
Expert: The vast majority of people such as rhinitis and pharyngitis can be vaccinated against the new crown vaccine
Time of Update: 2021-04-17
Regarding allergies, Wang Huaqing pointed out that if the vaccinators are confirmed to have acute allergic symptoms due to the new crown vaccine after the investigation and diagnosis expert group, the vaccinators cannot receive the second shot.
-
The mortality rate of severe COVID-19 patients has been reduced by 24
Time of Update: 2021-03-20
COVID-19 management FDAThe trial data of this critically ill population mainly include the following: 1) Compared with the placebo group, the all-cause mortality of the leronlimab group (the primary endpoint of the study) was reduced by 24%; 2) compared with the placebo group, the leronlimab group of patients The average length of stay in the hospital was reduced by 6 days; 3) In addition, patients in the leronlimab group were more likely to be discharged on day 28 (28% vs.
-
NICE supports AbbVie's Rinvoq treatment for rheumatoid arthritis
Time of Update: 2021-03-06
She added: "We are optimistic that we can also make positive claims decisions for those patients with serious illnesses who currently have limited treatment options." (cyy123.com) : NICE backs AbbVie's Rinvoq for severe active rheumatoid arthritis
-
Incyte Jak1 inhibitors were not confirmed in GVHD trials
Time of Update: 2021-03-03
Incyte announced the latest results from its Phase II study, which evaluated Itacitinib (formerly incb039110) in a combined treatment with corticosteroids to treat patients who had not received acute graft anti-host disease (gvhd).
-
Biodesix is working with Immodulon on pancreatic cancer treatment
Time of Update: 2021-02-25
The partnership will focus on analyzing circulating proteomics in patients with advanced pancreatic cancer treated with IMM-101 using the Biodesix Dignostic Cortex machine learning platform.
IMM-101 is a research immunotherapy candidate being developed by Immodulon for a variety of tumor types, including advanced pancreatic cancer.
-
Develop an innovative antibody therapy for influenza GlaxoSmithKline and Vir Extended Collaboration
Time of Update: 2021-02-23
In addition, the two sides will undertake two new research and development projects: the first is to expand existing functional genomics collaborations to develop new targets for the treatment of other respiratory viruses, and the second will use Vir's antibody technology platform to develop three neutral and monoclonal antibody therapies targeting non-flu pathogens.
-
First-tier urban residential land was snapped up in April floor price premium rate is a record high
Time of Update: 2021-02-13
According to the Central Plains Real Estate Market Research Department statistics show that since the beginning of April, the first-tier urban residential land transaction floor price, premium rate are record, the average floor price reached 16917 yuan per square meter, the premium rate of 63.7%.
-
Will the autumn/winter outbreak make a comeback? How long will it last? Expert answers
Time of Update: 2020-11-27
How to judge the source of the new crown virus strain in Beijing, autumn and winter outbreak will make a comeback?
